RESIRJJA Trademark

Trademark Overview


On Friday, July 17, 2020, a trademark application was filed for RESIRJJA with the United States Patent and Trademark Office. The USPTO has given the RESIRJJA trademark a serial number of 90058878. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, September 5, 2022. This trademark is owned by Sierra Oncology, Inc.. The RESIRJJA trademark is filed in the Pharmaceutical Products, Computer & Software Services & Scientific Services, and Medical & Beauty Services & Agricultural Services categories with the following description:

Pharmaceutical preparations and drugs for the treatment of cancer, namely, Myelofibrosis (MF); pharmaceutical preparations and drugs for the treatment of cancer and tumors, treatment of blood diseases or disorders, bone and bone marrow diseases, and cancers associated with blood diseases and/or disorders; Biological and chemical preparations for the treatment of cancer; Pharmaceutical products, preparations, and compounds for the prevention and treatment of cancer and tumors, treatment of blood diseases or disorders, bone and bone marrow diseases, and cancers associated with blood diseases and/or disorders; Pharmaceutical preparations and substance for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; medical reagents; Medical diagnostic reagents, ...

Medical services; medical testing services; DNA screening and analysis services for medical purposes

Pharmaceutical research and development; development of pharmaceutical preparations and drugs; development of pharmaceutical preparations and drugs for the treatment of blood diseases, bone and bone marrow diseases, and cancers; scientific research and development; scientific laboratory services; medical laboratory services; conducting clinical trials for others; conducting clinical trial for others regarding pharmaceutical preparations and drugs in the field of blood diseases, bone and bone marrow diseases, and cancers; DNA screening and analysis services for scientific research purposes
resirjja

General Information


Serial Number90058878
Word MarkRESIRJJA
Filing DateFriday, July 17, 2020
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, September 5, 2022
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, June 8, 2021

Trademark Statements


Goods and ServicesPharmaceutical preparations and drugs for the treatment of cancer, namely, Myelofibrosis (MF); pharmaceutical preparations and drugs for the treatment of cancer and tumors, treatment of blood diseases or disorders, bone and bone marrow diseases, and cancers associated with blood diseases and/or disorders; Biological and chemical preparations for the treatment of cancer; Pharmaceutical products, preparations, and compounds for the prevention and treatment of cancer and tumors, treatment of blood diseases or disorders, bone and bone marrow diseases, and cancers associated with blood diseases and/or disorders; Pharmaceutical preparations and substance for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; medical reagents; Medical diagnostic reagents, assays, and test kits for testing of body fluids; cells, protein molecules, and molecular compounds in the nature of drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals for medical purposes; DNA damage response assets, namely, pharmaceutical preparations for the treatment of conditions associated with DNA damage, namely cancer, for medical use
Goods and ServicesMedical services; medical testing services; DNA screening and analysis services for medical purposes
Goods and ServicesPharmaceutical research and development; development of pharmaceutical preparations and drugs; development of pharmaceutical preparations and drugs for the treatment of blood diseases, bone and bone marrow diseases, and cancers; scientific research and development; scientific laboratory services; medical laboratory services; conducting clinical trials for others; conducting clinical trial for others regarding pharmaceutical preparations and drugs in the field of blood diseases, bone and bone marrow diseases, and cancers; DNA screening and analysis services for scientific research purposes

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, August 14, 2020
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateFriday, August 14, 2020
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateFriday, August 14, 2020
Primary Code044
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameSierra Oncology, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressWilmington, DE 19808

Party NameSierra Oncology, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressVancouver, B.C. V6C3E8
CA

Trademark Events


Event DateEvent Description
Wednesday, October 19, 2022APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Wednesday, October 19, 2022TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, October 19, 2022TEAS CHANGE OF OWNER ADDRESS RECEIVED
Wednesday, October 12, 2022TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, October 12, 2022TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Wednesday, October 12, 2022ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Wednesday, October 12, 2022TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Tuesday, September 6, 2022ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, September 5, 2022ABANDONMENT - NO USE STATEMENT FILED
Thursday, February 3, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, February 1, 2022SOU EXTENSION 1 GRANTED
Tuesday, February 1, 2022SOU EXTENSION 1 FILED
Tuesday, February 1, 2022TEAS EXTENSION RECEIVED
Tuesday, August 3, 2021NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, June 8, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, June 8, 2021PUBLISHED FOR OPPOSITION
Wednesday, May 19, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, May 5, 2021APPROVED FOR PUB - PRINCIPAL REGISTER
Thursday, April 29, 2021TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, April 29, 2021CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, April 29, 2021TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, April 27, 2021TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, April 27, 2021TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Tuesday, April 27, 2021ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Tuesday, April 27, 2021TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Friday, October 30, 2020NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, October 30, 2020NON-FINAL ACTION E-MAILED
Friday, October 30, 2020NON-FINAL ACTION WRITTEN
Friday, October 30, 2020ASSIGNED TO EXAMINER
Friday, August 14, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Tuesday, July 21, 2020NEW APPLICATION ENTERED IN TRAM